Phaseline

Companies › Navamedic

Navamedic: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Levodopa
Dopamine D3 receptor agonist
DRD3Phase 4PARKINSON DISEASE (Disorder)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07839793LevodopaPhase 4PARKINSON DISEASE (Disorder)NeurologyMar 2027

Targets

DRD3 (1)

Companies with the same targets

LB Pharmaceuticals Gedeon Richter Serina Therapeutics Boryung Pharmaceutical Anxo Pharmaceutical Mapi Pharma AbbVie NeuroDerm MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

Companies built like this

Danyang Huichuang Medical Equipment Alasht Pharmed Sound Wave Innovation NeuroDerm Capricor

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.